Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
Last trade$28.17
Day change-$0.285 (-1.00%)
Day range$27.50 – $28.87
Volume261,408
Market cap$3.56B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PBLS.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PBLS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$2.11M
$148K
Cost of revenue
$0
$0
Gross profit
$2.11M
$148K
Selling, general and administrative
$11.25M
$11.66M
Research and development
$45.6M
$39.38M
Total operating expenses
$56.85M
$51.03M
Operating income
-$54.74M
-$50.89M
Interest expense
-$124K
-$210K
Income before taxes
-$44.49M
-$46.91M
Income taxes
$0
$0
Net income
-$44.49M
-$46.91M
Net income attributable to common shareholders
-$44.49M
-$66.96M
EBITDA
-$54.13M
-$50.89M
Basic earnings per share
-$0.36
-$2.32
Diluted earnings per share
-$0.36
-$2.32
Recent news
Company coverage with links to the original publishers.
Parabilis Medicines (PBLS) has a consensus price target of $41, suggesting 44.1% upside potential from its current price of $28.45. The stock has gained 12.2% over the past four weeks. Analysts have revised earnings estimates higher by 17.2% over the last 30 days, and PBLS holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as they are often overly optimistic.
Parabilis Medicines announced updated Phase 1/2 data for zolucatetide, a first-in-class β-catenin:TCF inhibitor, showing a 72.2% objective response rate and 100% disease control rate in desmoid tumor patients at the 32-week landmark. The company has reached FDA alignment on the Phase 3 PEDESTAL trial design, dosing regimen, and primary endpoint, with trial initiation planned for H1 2027 and topline results expected in 2029.
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., an accomplished oncology drug development leader with over 30 years of experience and two decades at Johnson & Johnson, to its Board of Directors. Dr. Tendler will continue his role as scientific advisor while joining the board to support the company's advancement of zolucatetide across multiple indications and its broader pipeline of Helicon therapeutics.
Parabilis Medicines raised $670 million in the largest biotech IPO on record, soaring 58% on its first trading day. The company's innovative Helicon platform targets previously 'undruggable' proteins for cancer treatment. While the technology shows promise with lead candidate zolucatetide entering phase 3 trials, the company faces significant losses ($145 million last year) and remains years away from generating revenue, making it suitable only for aggressive investors willing to wait several years.
Parabilis Medicines (NASDAQ: PBLS), a clinical-stage biopharmaceutical company, announced the successful closing of its upsized IPO on June 11, 2026, raising $770.5 million in gross proceeds from 38.5 million shares at $20 per share, plus an additional $75 million from a concurrent private placement with Regeneron Pharmaceuticals. The company has raised over $1.2 billion in total funding in 2026 to support development of its proprietary Helicons™ therapeutic platform targeting undruggable protein targets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.